Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
China Just Got A Lot Closer To Its First-Ever Manned Moon Landing - 2Who plays Moana in the live-action remake? What to know about Catherine Lagaʻaia.
- 321 Things You Ought to Never Share with Your Childless Companion
- 47 Powerful Techniques to Boost Efficiency with Your Cell Phone: A Far reaching Guide
- 5The Best 15 Applications for Efficiency and Association
- The most effective method to Quick Track Your Outcome in Advanced Showcasing with a Web-based Degree
- Palestinians forced from West Bank refugee camps left in limbo as Israeli demolitions go on
- Venus shines at its best in spring and summer 2026 — here's what to look for
- IDF: Staying in West Bank refugee camps will quell lone-wolf terror
- The Land Rover Freelander Is Back—But It’s No Longer a Land Rover
- The Strait of Hormuz Isn’t Just an Oil Problem, It’s Now a Food Problem
- Landon Donovan knew he couldn’t hide his hair loss. So he turned to fans for help.
- Picking the Right Pot for Your Plants: An Aide for Plant Devotees
- Vote in favor of the pasta that makes good dieting pleasant!
